Iovance Biotherapeutics (IOVA) has had the highest return since January 1, 2026 by a mid-cap US stock, returning 389.9%.
| ASSET | % RETURN |
|---|---|
Iovance Biotherapeutics (IOVA) | 389.93% |
10X Genomics (TXG) | 328.33% |
Twist Bioscience (TWST) | 318.37% |
MaxLinear (MXL) | 300% |
Erasca (ERAS) | 260.92% |
Abcellera Biologics (ABCL) | 245.03% |
CareDx (CDNA) | 239.7% |
Pulse Biosciences (PLSE) | 221.26% |
Veradermics (MANE) | 220.06% |
Okeanis Eco Tankers (ECO) | 218.6% |
Kodiak Sciences (KOD) | 207.24% |
AXT (AXTI) | 199.24% |
Calumet Specialty Products Partners (CLMT) | 192.11% |
Aehr Test Systems (AEHR) | 188.3% |
Penguin Solutions (PENG) | 187.22% |
Delek US Energy (DK) | 162.47% |
Ringcentral (RNG) | 161.62% |
International Seaways (INSW) | 161.62% |
Hyperliquid Strategies Inc Common Stock (PURR) | 156.94% |
Iridium Communications (IRDM) | 152.91% |
CVR Energy (CVI) | 149.85% |
Tango Therapeutics (TNGX) | 149.04% |
Spyre Therapeutics (SYRE) | 143.89% |
Enliven Therapeutics (ELVN) | 140.77% |
Lindblad Expeditions (LIND) | 138.93% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.